Ying-Jie Jia1, Xiao-Jiang Li, Chao Li, Cheng Zhao. 1. Department of Tumor, First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300193, China.
Abstract
OBJECTIVE: To observe the clinical efficacy of yiqi jiedu quyu recipe (YJQR) combined endocrine therapy in treating advanced prostate cancer (APC). METHODS:Totally 44 APC patients were randomly assigned to the combination group (23 cases) and the control group (21 cases). All patients received endocrine therapy for treating PC in Guidelines for Diagnosis and Treatment of Urological Diseases in China. After 6 months of treatment serum prostate specific antigen (PSA), free PSA (f-PSA), hemoglobin (Hb), Tcell subsets, natural kill (NK) cells, QLQ-C30 scale, Chinese medical symptoms score, I -PSS score, as well as the incidence of tidal fever were observed. RESULTS: After treatment the PSA, f-PSA, and Hb were improved in the combination group, showing statistical difference when compared with before treatment (P <0.05). Besides, better effects were obtained in the combination group (P <0.05, P <0.01). After treatment CD3, CD4, CD8, CD4/CD8, and NK cell levels were also improved in the combination group, showing statistical difference when compared with before treatment (P <0.05). Besides, better effects were obtained in the combination group (P <0.01). The quality of life (QOL), emotional function, Chinese medical symptoms score, and I -PSSsymptom score were improved in the two groups (P <0. 05,P <0. 01). Besides, better effects in the aforesaid indices and the incidence of tidal fever were obtained in the combination group (P <0.05). CONCLUSION:YJQR combined endocrine therapy could obviously improve APC patients' QOL, reduce adverse reactions of Western medical treatment, improve the immune function, and enhance therapeutic effects of endocrine therapy.
RCT Entities:
OBJECTIVE: To observe the clinical efficacy of yiqi jiedu quyu recipe (YJQR) combined endocrine therapy in treating advanced prostate cancer (APC). METHODS: Totally 44 APCpatients were randomly assigned to the combination group (23 cases) and the control group (21 cases). All patients received endocrine therapy for treating PC in Guidelines for Diagnosis and Treatment of Urological Diseases in China. After 6 months of treatment serum prostate specific antigen (PSA), free PSA (f-PSA), hemoglobin (Hb), Tcell subsets, natural kill (NK) cells, QLQ-C30 scale, Chinese medical symptoms score, I -PSS score, as well as the incidence of tidal fever were observed. RESULTS: After treatment the PSA, f-PSA, and Hb were improved in the combination group, showing statistical difference when compared with before treatment (P <0.05). Besides, better effects were obtained in the combination group (P <0.05, P <0.01). After treatment CD3, CD4, CD8, CD4/CD8, and NK cell levels were also improved in the combination group, showing statistical difference when compared with before treatment (P <0.05). Besides, better effects were obtained in the combination group (P <0.01). The quality of life (QOL), emotional function, Chinese medical symptoms score, and I -PSS symptom score were improved in the two groups (P <0. 05,P <0. 01). Besides, better effects in the aforesaid indices and the incidence of tidal fever were obtained in the combination group (P <0.05). CONCLUSION: YJQR combined endocrine therapy could obviously improve APCpatients' QOL, reduce adverse reactions of Western medical treatment, improve the immune function, and enhance therapeutic effects of endocrine therapy.